Noguchi, Shinzaburo
Ellis, Matthew J.
Robertson, John F. R.
Thirlwell, Jackie
Fazal, Mehdi
Shao, Zhimin
Funding for this research was provided by:
AstraZeneca
Article History
Received: 6 October 2017
Accepted: 18 January 2018
First Online: 15 February 2018
Compliance with ethical standards
:
: The study was conducted in accordance with the Declaration of Helsinki, the International Conference on Harmonisation, and Good Clinical Practice Guidelines. An ethics committee or institutional review board approved the final protocol at each study site.
: All patients provided written, informed consent.
: Shinzaburo Noguchi has been an advisor for Taiho, and has received research funding from AstraZeneca, Novartis, Chugai, Daiichi-Sankyo, Takeda, Pfizer, Ono, Taiho, and Eisai, and honoraria from AstraZeneca, Novartis, and Chugai. Matthew J. Ellis holds stock and has a leadership position with Bioclassifier LLC, which derives royalties and other income from a sublicense to Nanostring LLC for PAM50-based diagnostics, including Prosigna; he has been an ad hoc consultant for, and received honoraria and research funding from, AstraZeneca, and has also been a consultant for Pfizer, Puma and Novartis. John F. R. Robertson has been a consultant for, and has received honoraria from, AstraZeneca and Bayer AG, has received research funding from AstraZeneca, Bayer AG, and Novartis, has provided expert testimony for AstraZeneca, holds stocks or other ownership with Oncimmune, and holds stock options with Carrick Therapeutics. Jackie Thirlwell is an employee of JMT Statistics Ltd, and is under contract to provide statistical support to AstraZeneca. Mehdi Fazal is an employee of AstraZeneca. Zhimin Shao has no conflicts of interest to disclose.